> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BIO on FDA Data, Technology Plan
- URL: https://www.fdaweb.com/bio-on-fda-data-technology-plan/
- Published: 2023-06-13T12:00:00.000Z
- Updated: 2026-09-14T18:38:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154682

The Biotechnology Innovation Organization (BIO) says it applauds FDA efforts to embark on a data and technology modernization strategy consistent with PDUFA 7 commitments and FY 2023 Omnibus Bill requirements. “BIO encourages FDA to think strategically and would welcome opportunities to provide feedback as FDA’s strategy evolves,” the association [comment letter](https://downloads.regulations.gov/FDA-2023-N-1052-0054/attachment%5F1.pdf?ref=fdaweb.com) says.

The trade group suggests de-emphasizing the importance of upgrading the Electronic Submissions Gateway to the cloud, and instead focusing on “more dynamic and modern data exchange mechanisms with a goal of working towards a ‘real-time’ submission.” It also asks the agency to disclose any plans to leverage the use of generative artificial intelligence and natural language processing in reviewing applications.

The letter provides both general and specific comments.